Skip to main content
Not sure where to start? Get matched →
All answers

Anti-Aging · Reference

Ipamorelin vs CJC-1295: Two Receptors, One Pulse, and Why They Are Usually Combined

This page explains each on its own terms, puts them side by side, covers what the research does and does not show, where each stands with the FDA, how each is dosed, what each costs at Pepti, and who tends to suit which.

Ipamorelin (Injectable)
Ipamorelin$239/mo

Ipamorelin and CJC-1295 both prompt the pituitary to release its own growth hormone, but they do it through two different receptors, which is why they are more often combined than chosen between. Ipamorelin is a five-amino-acid peptide that mimics ghrelin at the growth hormone secretagogue receptor and was described in 1998 as the first selective secretagogue, releasing growth hormone without raising cortisol in animal work. CJC-1295 is a modified fragment of growth-hormone-releasing hormone (GHRH) that acts at the GHRH receptor; the version used in compounded blends is the short-acting form without DAC. At Pepti, ipamorelin is available on its own, while CJC-1295 is supplied only alongside ipamorelin in one vial. Both are prescription-only, compounded by a licensed US pharmacy, and neither is FDA approved.

This page explains each on its own terms, puts them side by side, covers what the research does and does not show, where each stands with the FDA, how each is dosed, what each costs at Pepti, and who tends to suit which.

Ipamorelin vs CJC-1295

The short answer

If your main goal is The usual prescription What is in it Price
The ghrelin-receptor signal alone, to see how you respond Ipamorelin 5 mg ipamorelin in a 5 mL vial (1 mg/mL) $239/mo
Both signals in one injection CJC-1295 / Ipamorelin 6 mg CJC-1295 and 12 mg ipamorelin in a 5 mL vial $239/mo
Ipamorelin with the GHRH analogue that has the longest human record Ipamorelin + Sermorelin 10 mg ipamorelin and 10 mg sermorelin in a 5 mL vial $219/mo
Ipamorelin with the GHRH analogue that has trial data on abdominal fat Tesamorelin + Ipamorelin 10 mg tesamorelin and 5 mg ipamorelin in a 5 mL vial $259/mo
CJC-1295 and ipamorelin aimed at sleep SERENITY Blend DSIP, Selank, CJC-1295 and ipamorelin $279/mo

Every figure is an all-in monthly price covering the medication, physician review, refill management and shipping. There is no separate membership fee. Current pricing always lives on each product page; the table is a guide to which product fits which goal.

Ipamorelin vs CJC-1295

Ipamorelin on its own terms

  • What it is

    Ipamorelin is a pentapeptide, sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2, two of its five amino acids unnatural so it survives long enough to act. It imitates ghrelin, the stomach hormone that signals hunger and tells the pituitary to release growth hormone. It is not growth hormone and contains none. The full reference is at what is ipamorelin.

  • Where it came from

    Ipamorelin was developed at Novo Nordisk in the 1990s. The founding paper, in the European Journal of Endocrinology in 1998, called it "the first selective growth hormone secretagogue": in pigs, older peptides such as GHRP-6 and GHRP-2 released growth hormone along with ACTH and cortisol, while ipamorelin released growth hormone at comparable potency without raising either above what GHRH produced. It was later tested in people for postoperative ileus, a bowel-recovery problem after surgery; that programme was discontinued.

  • How ipamorelin is described to work

    • The ghrelin receptor. It binds GHS-R1a on pituitary cells and triggers a single pulse of growth hormone rather than a sustained rise. In the human volunteer study, the pulse peaked at about 40 minutes and fell to negligible levels.
    • Selectivity. In animal work it did not raise cortisol or prolactin. The human volunteer study measured growth hormone only, so in people the selectivity is inferred, not measured.
    • Removing a brake. At the hypothalamus it is described as reducing somatostatin, the signal that holds growth hormone back.
    • Gut motility. Ghrelin receptors also sit on gut nerves, which is what took it into the ileus trials.
  • What human data exists for ipamorelin

    Study Who What was reported
    1999, Pharmaceutical Research Healthy male volunteers, intravenous, five dose levels Dose-proportional levels, a two-hour half-life, one sharp growth hormone pulse at every dose
    2014, International Journal of Colorectal Disease 114 adults after bowel surgery, intravenous, randomised and placebo-controlled Not statistically different from placebo; development stopped

    There are no randomised human trials of ipamorelin for sleep, recovery, body composition or any wellness use, and no human data for the subcutaneous route.

Ipamorelin vs CJC-1295

CJC-1295 on its own terms

  • What it is

    CJC-1295 starts from the first 29 amino acids of GHRH, the hypothalamic signal that tells the pituitary to release growth hormone. That 29-amino-acid fragment on its own is sermorelin. CJC-1295 changes four positions along the chain to protect it from the enzyme DPP-IV, which breaks native GHRH down within minutes. A 2005 paper in Endocrinology described the design.

  • With DAC and without DAC

    CJC-1295 comes in two forms. The version in the 2006 human trials carried a "drug affinity complex" (DAC), a tag that binds it to albumin in the blood so it keeps circulating for about a week. The version in compounded blends, including Pepti's, is CJC-1295 without DAC, also called modified GRF (1-29), which lasts roughly half an hour. That is why it is dosed daily and paired with ipamorelin for one pulse at a time. The full comparison is at CJC-1295 with DAC vs without DAC.

  • How CJC-1295 is described to work

    • The GHRH receptor. It binds the GHRH receptor on pituitary somatotroph cells, raising cyclic AMP and driving both release of stored growth hormone and synthesis of more.
    • Pulses preserved. A 2006 paper in the Journal of Clinical Endocrinology and Metabolism sampled blood every ten minutes in healthy adults on the DAC form and found growth hormone still released in pulses, with more hormone per pulse.
    • In animals. A 2006 study in the American Journal of Physiology reported that once-daily CJC-1295 normalised growth in mice engineered to lack GHRH.
  • What human data exists for CJC-1295

    The 2006 healthy-adult trials of the DAC form reported growth hormone rising two- to ten-fold for six days or more and IGF-1 rising 1.5- to three-fold for nine to eleven days after one injection, described as well tolerated. There are no human trials of the no-DAC form on its own; its human evidence is borrowed from the shared chain. There are no randomised trials of either form for sleep, recovery or body composition.

Ipamorelin vs CJC-1295

Head to head

Ipamorelin CJC-1295 (no DAC)
What it imitates Ghrelin GHRH (growth-hormone-releasing hormone)
Receptor GHS-R1a (ghrelin receptor) GHRH receptor
Length 5 amino acids 29 amino acids with four substitutions
How long it lasts Half-life about two hours (intravenous study) Roughly half an hour
Extra effect Lowers the somatostatin brake Drives growth hormone synthesis as well as release
Effect on cortisol Not raised in animal work Not described as raising it
Human data One volunteer pharmacology study; one negative ileus trial 2006 trials of the DAC form only
Outcome trials for sleep, recovery, body composition None None
Sold alone at Pepti Yes, $239 a month No; only with ipamorelin, $239 a month

The real difference is the door, not the strength

People often ask which is "stronger." They are not two strengths of one thing. The pituitary listens to two inputs, GHRH from the hypothalamus and ghrelin-type signals from the gut, through separate receptors on the same cells. Ipamorelin supplies the ghrelin signal; CJC-1295 supplies the GHRH signal. Together they have been described as more than additive since the early 1990s, because one also takes the somatostatin brake off. That is the whole reason CJC-1295 / Ipamorelin exists as one vial. Neither is a substitute for growth hormone; both depend on a pituitary that can still respond.

Ipamorelin vs CJC-1295

Who suits which

  • Ipamorelin alone

    Ipamorelin on its own is described as the gentler option and a reasonable first step when a physician wants to see how a person responds to the ghrelin signal before adding a second compound. It is taken at bedtime so the induced pulse lands on top of the natural nighttime pulse. More detail: ipamorelin benefits and ipamorelin dosage.

  • CJC-1295 with ipamorelin

    The combination is the more common prescription because the two signals together produce a larger pulse than either alone. It is taken on an empty stomach, because glucose and fatty acids after a meal blunt the growth hormone response. More detail: CJC-1295 / Ipamorelin benefits and is CJC-1295 / Ipamorelin safe.

  • Ipamorelin with a different GHRH analogue

    If a physician prefers the GHRH analogue with the longest human record, Ipamorelin + Sermorelin pairs ipamorelin with sermorelin. If visceral fat is the focus, Tesamorelin + Ipamorelin pairs it with tesamorelin, the one GHRH analogue with randomised human trials on abdominal fat in a specific population. See sermorelin vs tesamorelin vs ipamorelin and CJC-1295 vs tesamorelin.

Ipamorelin vs CJC-1295

When neither is the right first step

Situation What makes more sense
You may have true growth hormone deficiency An endocrinologist; it has its own testing and an FDA-approved treatment
Weight is the main goal Semaglutide or tirzepatide, which have large randomised trials; in mice, ipamorelin raised body weight and food intake
Sleep is the only goal DSIP or the SERENITY Blend
A specific soft-tissue injury BPC-157 or TB-500
Diabetes or impaired glucose tolerance Raise it at intake; growth hormone opposes insulin

Ipamorelin vs CJC-1295

Where each stands with the FDA

Ipamorelin CJC-1295
2023 Category 2 of the 503A interim list Category 2 of the 503A interim list
Left Category 2 27 September 2024, when the nomination was withdrawn September 2024, when the nomination was withdrawn
Advisory committee 29 October 2024: 0 for, 12 against, 1 abstention, evaluated for growth hormone deficiency and postoperative ileus 4 December 2024: 0 to 13 against the free base and 1 to 12 against the acetate, evaluated for growth hormone deficiency; DAC forms also voted against
Current list (14 May 2026) In no category In no category
Final FDA determination Not issued Not issued

The committee evaluated each substance for the specific uses in its nomination, against FDA-approved drugs that already exist for those uses. A vote is a recommendation, not a ban. Both remain legal to prescribe and dispense as compounded medications, and compounded medications are not FDA approved. Are peptides FDA approved explains the difference.

Ipamorelin vs CJC-1295

Dosing, side by side

Both are injected under the skin (subcutaneously) into the abdomen or thigh, rotating sites, Monday through Friday with weekends off. The figures below are arithmetic on the vial strength, on a U-100 insulin syringe where 1 unit is 0.01 mL.

Ipamorelin CJC-1295 / Ipamorelin
Vial 5 mL at 1 mg/mL (5 mg) 5 mL at 1.2 mg/mL CJC-1295 + 2.4 mg/mL ipamorelin
Printed directions Inject 0.25 mL (25 units) subcutaneously Monday through Friday nights at bedtime Inject 0.25 mL (25 units) subcutaneously once daily Monday through Friday on an empty stomach
Per dose 0.25 mg (250 mcg) ipamorelin 0.3 mg CJC-1295 and 0.6 mg ipamorelin
Doses per vial 20, about 4 weeks 20, about 4 weeks

For the combination vial, here is what different syringe marks would contain. This is math only, not a dosing suggestion:

Units mL CJC-1295 Ipamorelin
10 0.10 0.12 mg 0.24 mg
20 0.20 0.24 mg 0.48 mg
25 (typical printed directions) 0.25 0.30 mg 0.60 mg

One thing the table shows: a standard dose of the combination carries more ipamorelin (0.6 mg) than a standard dose of ipamorelin alone (0.25 mg), because the combination vial is more concentrated. Both are fixed by the formulation, and you never adjust one peptide against the other. Your directions are printed on the vial, and your physician sets them after reviewing your intake. Both ship refrigerated with ice packs, sterile syringes and alcohol prep pads; refills run every 28 days, one vial per fill. The combination is also available as a pre-filled Pen cartridge.

Bloodwork is not required for any Pepti treatment. If your physician wants labs for your care, they'll ask through your account.

Ipamorelin vs CJC-1295

Side effects

Ipamorelin. Reported as well tolerated in the volunteer study and the seven-day surgical trial. What is reported clinically is mostly short-lived: headache, flushing or warmth after injection, hunger, light-headedness, and injection-site redness or soreness. More: ipamorelin side effects.

CJC-1295 / Ipamorelin. The 2006 CJC-1295 trials reported mainly injection-site reactions and headache. Clinically, people report injection-site redness, a brief flush, headache, hunger, and, with the growth hormone rise, water retention or tingling in the hands.

For both, the class concerns of anything that raises growth hormone and IGF-1 apply: blood glucose can drift up, fluid can be retained, and because IGF-1 supports tissue growth, a personal history of cancer is raised at intake. Stop and contact your care team for any reaction that is severe or spreading. Difficulty breathing or swelling of the face or throat needs emergency care: call 911.

Ipamorelin vs CJC-1295

Who should not take either, or should discuss it first

Situation Why
Personal history of cancer IGF-1 supports tissue growth
Diabetes or impaired glucose tolerance Growth hormone opposes insulin
Pregnancy or breastfeeding Not used; safety data is absent
Tested athletes Growth hormone releasing factors and secretagogues are prohibited at all times under the World Anti-Doping Code

Ipamorelin vs CJC-1295

What the evidence shows, honestly

Both peptides are known to raise growth hormone in humans: ipamorelin in a 1999 intravenous volunteer study, CJC-1295 in the 2006 trials of the DAC form. Beyond that, the benefits people are prescribed them for, sleep, recovery and body composition, are inferred from what growth hormone does, not measured in any trial of either peptide or the blend. The only randomised trial of ipamorelin in patients did not beat placebo, and the no-DAC form of CJC-1295 has no trials of its own. The honest framing is "known to raise growth hormone; benefits beyond that are inferred from physiology and clinical experience."

Ipamorelin vs CJC-1295

Where to get ipamorelin or CJC-1295 prescribed

Neither can be bought legitimately without a prescription. Sites selling them "for research use only" are not accountable for what is in the vial: identity, purity, sterility and concentration are untested. The prescription route:

  1. Complete a free online intake covering your history, medications and what you want help with.
  2. A physician licensed in your state reviews it, usually within 24 hours.
  3. If it is appropriate, a PCAB-accredited, FDA-registered US 503A pharmacy compounds it to that prescription. Lot test results are published at /quality/lab-results.
  4. It ships refrigerated with your directions printed on the vial.
  5. Your care team stays reachable for questions and side effects.

Pepti is cash-pay and does not bill insurance. Step-by-step pages: how to get ipamorelin prescribed online and how to get CJC-1295 / Ipamorelin prescribed online.

References

What this is based on.

References

  1. Raun K, Hansen BS, Johansen NL, et al.. Ipamorelin, the first selective growth hormone secretagogue · European Journal of Endocrinology (1998) · PMID 9849822
  2. Greenwood-Van Meerveld B, Tyler K, Mohammadi E, Pietra C. Efficacy of ipamorelin, a ghrelin mimetic, on gastric dysmotility in a rodent model of postoperative ileus · Journal of Experimental Pharmacology (2012) · PMID 27186127
  3. Andersen NB, Malmlöf K, Johansen PB, et al.. The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation of adult rats · Growth Hormone & IGF Research (2001) · PMID 11735244
  4. Lall S, Tung LY, Ohlsson C, Jansson JO, Dickson SL. Growth hormone (GH)-independent stimulation of adiposity by GH secretagogues · Biochemical and Biophysical Research Communications (2001) · PMID 11162489
  5. Adeghate E, Ponery AS. Mechanism of ipamorelin-evoked insulin release from the pancreas of normal and diabetic rats · Neuro Endocrinology Letters (2004) · PMID 15665799
  6. Semenistaya E, Zvereva I, Thomas A et al.. Determination of growth hormone releasing peptides metabolites in human urine after nasal administration of GHRP-1, GHRP-2, GHRP-6, Hexarelin, and Ipamorelin · Drug Test Anal (2015) · PMID 25869809
  7. Nass R, Pezzoli SS, Oliveri MC et al.. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial · Ann Intern Med (2008) · PMID 18981485
  8. Moreno-Reyes R, Kerkhofs M, L'Hermite-Balériaux M, Thorner MO et al.. Evidence against a role for the growth hormone-releasing peptide axis in human slow-wave sleep regulation · Am J Physiol (1998) · PMID 9612233
  9. Copinschi G, Leproult R, Van Onderbergen A, Caufriez A et al.. Prolonged oral treatment with MK-677, a novel growth hormone secretagogue, improves sleep quality in man · Neuroendocrinology (1997) · PMID 9349662

Citations are provided for educational purposes. They do not constitute medical advice. Always discuss any peptide protocol with your prescribing physician.

Common questions

Ipamorelin vs CJC-1295, answered.

Ipamorelin mimics ghrelin at the growth hormone secretagogue receptor; CJC-1295 is a modified GHRH fragment acting at the GHRH receptor. Both prompt the pituitary to release its own growth hormone, through different receptors on the same cells.

Next step

See what a physician recommends for you.

A licensed physician in your state reviews your intake and decides what is appropriate. A consultation does not guarantee a prescription.